Human PAI-1 (stable mutant, no LRP binding)

$715$1,170

Clear
SKU: HPAI-R76E-I91L Categories: ,

Product Description

Human PAI-1 (stable mutant, no LRP binding)

A substitution of Glutamic Acid for Arginine at position 76 greatly decreases the binding of this Human PAI-1 mutant to the low density lipoprotein receptor-related protein (LRP). The putative LRP binding exosite is thought to overlap with the heparin binding site on the PAI-1 molecule. Binding to LRP or similar receptors leads to the clearance of PAI-1 complexes. An additional mutation (Isoleucine 91 to Leucine) provides increased stability for use in long term binding experiments or in vivo studies. A human PAI-1 point mutation stable form (Catalog Number HPAI-I91L) is available as an LRP binding control PAI-1.

References:
Stefansson S. et al. (1998) J Biol Chem 273:6358-6366.

Gene ID: 5054
Swiss-Prot/UniProt ID: P05121

View sample datasheet
View sample certificate of analysis
View material safety data sheet
Ask a question about this product

Additional Information

Purity

Source

Molecular Weight

Extinction Coefficient

Species

Storage

Shipping Conditions

Expiration

Form

Buffer

Sample Size

Sample Concentration

Sample Volume

Gene Name

Gene ID

UniProt ID

1. Sashindranath M, Sales E, Daglas M et-al. The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humans. Brain. 2012;135 (Pt): 3251-64. doi:10.1093/brain/aws178Free text at pubmedPubmed citation

2. Simone TM, Higgins SP, Archambeault J, et al. A small molecule PAI-1 functional inhibitor attenuates neointimal hyperplasia and vascular smooth muscle cell survival by promoting PAI-1 cleavage. Cell Signal. 2015;27(5):923-33. Link to article